Company Overview
UROGEN PHARMA LTD.
URGNRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
110M
2025 FY
Net Income
-153M
2025 FY
Shares Outstanding
48M
2025 FY
EPS
-3.19USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1668243
Exchange
Nasdaq
Location
IL